New triple-drug approach targets hard-to-treat leukemia
NCT ID NCT06514261
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 26 times
Summary
This early-stage trial tests whether adding a new drug called iadademstat to two standard chemotherapy drugs (venetoclax and azacitidine) is safe and tolerable for adults with untreated acute myeloid leukemia (AML). The study enrolls 45 people with intermediate- or high-risk AML. Researchers aim to find the best dose and watch for side effects, while also tracking how well the cancer responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, 92612, United States
-
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio, 45219, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.